Key takeaways
- AMH comes from small early-stage follicles, so it tracks the size of the standing pool rather than the current cycle — and can be drawn on any day.
- It is essentially a one-way measurement: it declines with time and nothing raises it, so a lower repeat result is usually the passage of time.
- It predicts IVF response well, flags premature ovarian insufficiency, and gives a menopause horizon accurate to roughly three to four years.
- It does not grade egg quality or predict conception in a given month — ovarian reserve biomarkers did not predict fecundability in women without infertility.
- Hormonal contraception lowers it, PCOS raises it, and assays differ between laboratories, so track trends within one lab.
AMH is one of the few hormone tests that answers a question about quantity rather than function. It estimates how many follicles are still in the pool — not whether they work, not whether you will conceive this year, and not how you feel. Almost every misreading of an AMH result comes from asking it a question about quality or timing that it was never able to answer.
What AMH actually is
Anti-Müllerian Hormone is produced by the granulosa cells surrounding early-stage ovarian follicles — the small pre-antral and antral follicles that have begun to develop but have not yet been recruited into a cycle. Because each of those follicles contributes a small amount, the circulating level tracks the size of the standing pool: the follicles available to potentially ovulate over your remaining reproductive years (Dewailly et al., Hum Reprod Update 2014).
Higher AMH means a larger remaining reserve. Lower AMH means a smaller one. Near-zero AMH means the pool is close to exhausted.
Two properties follow from that mechanism and both matter practically. First, because the hormone comes from the background pool rather than the single dominant follicle of the current cycle, it does not swing across the month the way estradiol and FSH do — which is why it can be drawn on any day. Second, because it comes from a pool that only depletes, AMH is essentially a one-way measurement. It goes down with time and does not recover. Nothing you can buy raises it; a lower result on a repeat test is usually the passage of time, not a failure of management.
The name comes from a second, unrelated job: in male foetal development it causes the Müllerian ducts to regress. Its role as an ovarian reserve marker is a separate use of the same molecule.
Age-based ranges
| Age | Average AMH (ng/mL) | Optimal range |
|---|---|---|
| 25 | 3.5 | 2.0-6.0 |
| 30 | 2.5 | 1.5-4.5 |
| 35 | 1.8 | 1.0-3.5 |
| 40 | 1.0 | 0.5-2.5 |
| 45 | 0.4 | 0.1-1.5 |
| 50 | 0.1 | ≤0.5 |
Read these as population averages with wide individual spread, not targets. A woman of 35 below the average for her age is not automatically in trouble, and one above it has not bought extra years of fertility. The table is useful mainly for flagging a result markedly out of step with age — in either direction — as something needing an explanation.
What AMH predicts
- IVF response. Higher AMH predicts more eggs retrieved per stimulation cycle (Broer et al., Hum Reprod Update 2011). This is the use it performs best, because the question — how many follicles will respond to stimulation — is exactly the question the marker measures. It is also why fertility clinics use it for protocol selection rather than for prognosis.
- Premature ovarian insufficiency. A very low AMH for age suggests POI and warrants investigation rather than reassurance, particularly under 40, where the implications extend well beyond fertility to bone and cardiovascular health.
- Rough menopause timing. Very low AMH (under 0.2) suggests menopause within roughly two years.
- The fertility window. It gives a sense of how much time remains for a woman who wants biological children — as a planning horizon, not a countdown.
What AMH does not predict
- Whether you can conceive naturally this month. Pregnancy depends on the quality of the egg released this cycle, not the size of the pool it came from. In women without known infertility, biomarkers of ovarian reserve did not predict fecundability (Steiner et al., JAMA 2017). This is the single most consequential limitation, and the one most often reversed in the retelling.
- Egg quality. AMH counts; it does not grade. Quality declines with age largely through accumulating chromosomal errors in the egg, and no blood test captures that.
- Symptoms. Many women with low AMH have normal cycles and no menopausal symptoms — until they do not. The pool shrinking and the feedback loop destabilising are different events, and the second is what produces symptoms.
- How long until pregnancy occurs. Any number attached to that is a statistical average applied to an individual.
Why the same number can mean different things
An AMH result is not self-interpreting, and several common situations shift it without changing the underlying reserve.
Hormonal contraception suppresses the level modestly. A result taken on the combined pill is still informative but reads lower than the same ovary would produce off it — enough to matter if the number is being used to make a decision about egg freezing.
PCOS pushes it the other way. The characteristic feature is a large number of small antral follicles that do not progress to ovulation, and since those follicles are precisely what produces AMH, levels are typically high. A high AMH in a woman with irregular cycles is a finding to investigate, not a reassurance about fertility; the PCOS playbook covers the wider picture.
Assay differences mean results are not freely comparable between laboratories. If you are tracking change over time, use the same lab, and be sceptical of a dramatic difference between two providers before assuming your ovaries changed.
Ovarian surgery, chemotherapy and smoking all reduce reserve genuinely rather than artefactually — the number moves because the pool did.
Using it for fertility planning
The value of AMH is that it converts a vague anxiety into a dated decision. The decision it informs is almost always the same one: whether to act now or wait.
- AMH at 30: a data point in the egg-freezing question rather than an instruction. A low-for-age result at this stage is the most actionable version, because there is still time to act on it.
- AMH at 35: more pressing. Egg freezing is most cost-effective in the early-to-mid thirties, because both the number and the quality of eggs retrieved are better then.
- AMH falling quickly across repeat tests: a reason to bring the timeline forward, provided the tests came from the same laboratory.
For women actively trying to conceive, AMH adds relatively little. Age-adjusted natural fertility rates carry more of the useful information, and a normal AMH should never be the reason to delay an infertility workup that is otherwise indicated.
Menopause prediction
Longitudinal cohort work, including the Tehran Lipid and Glucose Study, shows AMH predicts menopause timing to within roughly three to four years (Tehrani et al., Aging Dis 2022). That is genuinely useful for a woman in her forties who wants to know roughly what part of the transition she is in. It is not precise enough to plan a specific year around.
Note what this does and does not tell you about symptoms. AMH describes the reserve; the symptom burden of perimenopause comes from the instability of the hormones the remaining follicles produce. A woman can have a low AMH and few symptoms, or a moderate AMH and a difficult transition. If the question is "what is happening to me right now", the relevant workup is a full hormone panel plus a symptom pattern — the perimenopause guide sets out that approach, and estrogen levels by age gives the broader trajectory.
When and how to test
- Any day of the cycle, unlike FSH, which is conventionally drawn on day three
- Usable on hormonal contraception, with the caveat that it reads slightly suppressed
- As part of a comprehensive female hormone panel rather than in isolation — see the complete hormone panel explained
- When fertility timing is an active question
- When perimenopause is suspected, alongside the markers that actually explain symptoms
- Repeat testing is worth doing only when a decision depends on the trend, and then from the same laboratory
The clinical pearl: AMH is a planning tool, not a fertility prediction. It tells you roughly how much reserve is left. It does not tell you whether that reserve is good quality, whether you will conceive this year, or how you will feel — and treating it as if it does is how a normal result delays a workup that should have happened.
Bottom line
AMH is produced by small ovarian follicles, so it estimates the size of the remaining pool and stays stable across the cycle. That makes it genuinely useful for predicting IVF response, identifying premature ovarian insufficiency, and giving a rough menopause horizon. It cannot grade egg quality, predict conception in any given month, or explain symptoms — and it reads low on contraception and high in PCOS, so the number needs its context. Used as one component of a full panel in a woman's thirties or forties, it converts an open-ended worry into a dated decision. Used alone, it is the lab most likely to be over-read in both directions. The 60-second assessment is a starting point for the wider workup.
Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.
